Tocagen Announces Potential Pricing for IPO
Tocagen expects to price more than 7 million shares in the range of $10 to $12 apiece for an initial public offering valued up to about $100 million.
Tocagen expects to price more than 7 million shares in the range of $10 to $12 apiece for an initial public offering valued up to about $100 million.
One independent research firm thinks that Snap has the potential to put up a fight against the likes of Facebook or Twitter, but it may take some time.
While many analyst calls are basic upgrades and downgrades, there are often some very unusual upgrades or positive calls for big upside to the analyst price targets. Here are five unusual upgrades and positive…
Pickup sales may account for more than 60% of all light vehicle sales in the month of March. Ford's F-Series trucks added to its market share lead last month.
A continuing slide in Jeep sales is too much for Fiat Chrysler to overcome, even with growing sales of minivans.
GM March sales were nearly 2% higher, but pickup sales dropped sharply and inventory level increased again.
Ford's March sales dropped 7.2% as passenger car sales tumbled by more than 25%. Even the company's top-selling F-Series pickups couldn't make up the difference.
One key analyst thinks that first-quarter results from banks will not be mind-blowing, but instead believes estimates are still biased upward as more rate hikes get built in, deposit betas remain low and credit…
Will China ascend to the environmental high moral ground now that the Trump administration has taken steps to revitalize the U.S. coal industry? Maybe, but not likely.
Tesla's market cap now is bigger than Ford's, primarily because Tesla sold more cars than expected in the first quarter, while Ford's sales have dropped sharply.
Jefferies analysts remain reasonably bullish, and in their top growth picks for the week the firm focuses on some stocks that could be top momentum stories for the second quarter.
Cloudera has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
NovoCure saw its shares skyrocket early on Monday after the firm provided an update for its late-stage cancer trial.
The top analyst upgrades, downgrades and initiations seen on Monday include Accenture, Ecolab, Huntington Bancshares, Oasis Petroleum, Snap and Under Armour.
For the past couple of months, Wall Street strategists and portfolio managers has been championing European stocks as better buys now than U.S. stocks.